Business Context and Reporting Period
This Form 8-K is filed by Salarius Pharmaceuticals, Inc. (not Decoy Therapeutics Inc.) on June 18, 2020, reporting an event that occurred on June 15, 2020. The Company is incorporated in Delaware and its common stock trades on The Nasdaq Capital Market under the symbol SLRX.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory compliance regarding stock listing status.
Material Changes
The primary material event is the resolution of a listing deficiency. The Nasdaq Listing Qualifications Department confirmed that the Company regained compliance with Nasdaq Listing Rule 5550(a)(2). Specifically, the closing bid price of the Company's common stock was at or above $1.00 per share for the last 10 consecutive business days (June 1 to June 12, 2020). The matter is now closed.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies beyond the resolution of the specific listing compliance issue.
Investor Verification Checklist
- Verify the current trading price of SLRX to ensure continued compliance with Nasdaq minimum bid price requirements.
- Confirm the Company's status as an emerging growth company (indicated as yes in the filing).
- Review subsequent filings for any new compliance notices or financial updates, as this 8-K contains no financial data.